Drug retention, efflux, and resistance in tumor cells

Cytometry

Volumn 29, Issue 4, 1997, Pages 279-285

  Krishan, Awtar ^a,b   Fitz, Catherine Morgan ^a   Andritsch, Ilia ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Drug efflux; Efflux blockers; Flow cytometry; Fluorescent dyes; LRP; MDR; MRP; Multiple drug resistance; Transport proteins

Indexed keywords

ACRIDINE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; CALCEIN; CARRIER PROTEIN; CARUBICIN; CHLORPROMAZINE; CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; FLUORESCENT DYE; GLYCOPROTEIN P; N TRIFLUOROACETYLDOXORUBICIN; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; RHODAMINE 123; TAMOXIFEN; TRIFLUOPERAZINE; VERAPAMIL; ZORUBICIN;

ANIMAL CELL; DRUG RETENTION; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; VAULT RIBONUCLEOPROTEIN PARTICLES;

ANIMALIA;

EID: 0031463901     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19971201)29:4<279::AID-CYTO3>3.0.CO;2-5     Document Type: Review

References (72)

1. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M, Kuwano M: Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine and chlorpromazine. J Natl Cancer Inst 76:839-844, 1986.
2. Almquist KC, Douglas WL, Hipfner DR, Mackie JE, Cole SPC, Deeley RG: Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55:102-110, 1995.
3. Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R, Suttle DP: Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase-II. In: Advances in Pharmacology, Vol 29B, L.F. Liu (ed). Academic Press, New York, 1994, pp 145-167.
4. Biedler JL: Drug resistance: Genotype versus phenotype. Thirty-second G.H.A. Clowes Memorial Award Lecture. Cancer Res 54:666-678, 1994.
5. Campos L, Guyotat D, Archimbaud E: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79:473-476, 1992.
6. Chambers TC, Zheng B, Kuo JF: Regulation by phorbol ester and protein kinase C inhibitors and by a protein phosphatase inhibitor (okaidic acid) of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Mol Pharmacol 41:1008-1015, 1995.
7. Chan HS, Thorner PS, Haddad G, Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990.
8. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992.
9. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JLM, Bertino JR: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Nat Acad Sci 86:695-698, 1988.
10. Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T, Padua RA: Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukemia. Br J Haematol 76:226-230, 1990.
11. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. Cancer 75:815-820, 1995.
12. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CWM, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:815-424, 1989.
13. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466-483, 1973.
14. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: Relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 48:3595-3602, 1988.
15. Durand RE: Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res 41:3495-3498, 1981.
16. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ: Functional detection of MDR1/p170 and MRP/p190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72:543-549, 1995.
17. Flens MJ, Zaman GJR, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GJ, van der Groep P, de Haas M, Meijer CJLM, Scheper RJ: Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247, 1996.
18. Frey T, Yue S, Haugland RP: Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance. Cytometry 20:218-227, 1995.
19. Ganapathi R, Grabowski D, Rouse W, Riegler F: Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res 44:5056-5061, 1981.
20. Germann UA, Chambers TC, Ambudkar SV, Pastan I, Gottesman MM: Effects of phosphorylation of P-glycoprotein on multidrug resistance. J Bioenerg Biomembr 27:53-61, 1995.
21. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, Higgins CF: Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271:13668-13674, 1996.
22. Gottesman, MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53:747-754, 1993.
23. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361, 1994.
24. Gros P, Dhir R, Croop J, Talbot F: A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdrl and mdr3 drug efflux pumps. Proc Natl Acad Sci 88:7289-7293, 1991.
25. Hollo Z, Homola L, Davis CW, Sakardi B: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384-388, 1994.
26. Inaba M, Kobayashi H, Sakurai Y, Johnson RK: Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39:2200-2203, 1979.
27. Izquierdo M, Scheffer G, Flens M, Giaccone G, Broxterman HJ, Meijer CJLM, van der Valk P, Scheper RJ: Broad distribution of the multidrug resistance-related vault lung protein in normal human tissues and tumors. Am J Pathol 148:877-887, 1996.
28. Izquierdo MA, van der Zee AGJ, Vermorken JB, ven der Valk P, Beliën JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, deVries EGE, Scheper RJ: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230-1235, 1995.
29. Jedlitschky G, Leier I, Buchholz U, Bamouin K, Kurz, G, Keppler, D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56:988-994, 1996.
30. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162, 1976.
31. Kartner N, Evernden-Porelle D, Bradley G, Ling V: Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316:820-823, 1985.
32. Kessel D, Botterill V, Wodinsky I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res 28:938-941, 1968.
33. Krishan A: Effect of drug efflux blockers on vital staining of cellular DNA with Hoechst 33342. Cytometry 8:642-645, 1987.
34. Krishan A: Heterogeneity of anthracycline retention and response to efflux blockers in human tumors. Cytometry 21:72-75, 1995.
35. Krishan A, Bourguignon LYW: Cell cycle related phenothiazine effects on adriamycin transport. Cell Bio Int Rep 8:449-457, 1984.
36. Krishan A, Ganapathi R: Laser flow cytometric studies on intracellular fluorescence of anthracyclines. Cancer Res 40:3895-3900, 1980.
37. Krishan A, Israel M, Modest EJ, Frei EI III: Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Res 36:2114-2116, 1976.
38. Krishan A, Sauerteig A, Andritsch I, Wellham L: Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia 11:1138-1146, 1997.
39. Krishan A, Sauerteig A, Gordon K: Effect of amphotericin B on adriamycin transport in P388 cells. Cancer Res 45:4097-4102, 1985.
40. Krishan A, Sauerteig A, Stein JH: A comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry 12:731-742, 1991.
41. Krishan A, Sauerteig A, Wellham L: Flow cytometric studies on modulation of cellular adriamycin retention by phenothiazines. Cancer Res 45:1046-1051, 1985.
42. Krishan A, Sridhar KS, Davila E, Vogel C, Sternheim W: Patterns of anthracycline retention modulation in human tumor cells. Cytometry 8:306-314, 1987.
43. Lee Y-I, Ramachandran C, Kunikane H, Wellham LL, Krishan A: Modulating effect of tamoxifen, verapamil and trifluoperazine on doxorubicin cytotoxicity in human breast cancer cell lines. Cellular Pharamacol 2:319-322, 1995.
44. Lelong EH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM, Willingham MC: Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Mol Pharmacol 40:490-494, 1991.
45. Leonesa F, Jacobson M, Boyle B, Lippman M, Roufogalis BD, Stratford IJ, Carmichael J: Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48:277-285, 1994.
46. Ling V: P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603-2609, 1992.
47. List A, Spier C, Grogan T, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2463-2469, 1996.
48. List AF: Multidrug resistance: Clinical relevance in acute leukemia. Oncology 7:23-28, 1993.
49. Müller M, Meuer C, Zaman GJR, Borst P, Cheper RJ, Mulder NH, de Vries EGE, Jansen PLM: Overexpression of the gene encoding the multidrug resistance-associated protein (MRP) results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037, 1994.
50. Nair S, Singh SV, Samy TS, Krishan A: Anthracycline resistance in murine leukemic P388 cells: Role of drug efflux and glutathione related enzymes. Biochem Pharmacol 39:723-728, 1990.
51. Nooter K, Bosman F, Burger H, Vanwingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AWM, Vandergaast A, Stoter G: Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7:75-81, 1996.
52. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JEY: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647, 1987.
53. Pastan I, Gottesman M: Multiple drug resistance in human cancer. NEJ Med 316:1388-1393, 1987.
54. Ramachandran C, Mead D, Wellham L, Sauerteig A, Krishan A. Expression of drug resistance associated mdr-1, GSTπ, and topoisomerase II genes during cell cycle. Biochem Pharm 49:545-552, 1995.
55. Ramu A, Glaubiger D, Magrath IT, Joshi A: Plasma membrane lipid structural order in doxorubicin-sensitive and resistant P388 cells. Cancer Res 43:5533-5537, 1983.
56. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clever HC, Scheper RJ: The drug resistance-related protein Lrp is the human major vault protein. Nat Med 1:578-582, 1995.
57. Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, van der Schoot E, Balm AJM, Meuer CJLM, Broxterman HJ, Kuiper CM, Lankelma J, Pinedo HM: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42:389-394, 1988.
58. Shalinsky DR, Andreeff M, Howell SB: Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res 50:7537-7543, 1990.
59. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J: Clinical reversal of multidrug resistance. Cancer Treat Res 73:149-165, 1994.
60. Skovsgaard T: Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38:1785-1791, 1978.
61. Sridhar K, Krishan A, Samy T, Sauerteig A, Wellham L, McPhee G, Duncan RA, Ardalan B, Benedetto P: Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother Pharmacol 31:423-430, 1993.
62. Sridhar KS, Krishan A, Samy TSA, Duncan RC, Sauerteig A, McPhee GV, Auguste ME, Benedetto PW, Waldman S: Phase I and pharmacokinetic studies of prochlorperazine 2-hour IV infusion as a doxorubicin efflux blocker. Can Chem Pharm 34:377-384, 1994.
63. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468, 1984.
64. Thomas GA, Barrand MA, Stewart S, Rabbitts PH, Williams ED, Twentyman PR: Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridization. Eur J Cancer 30A:1705-1709, 1994.
65. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL: High dose oral tamoxifen, a potential multidrug-resistance reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816, 1992.
66. Tsuruo T, Iida H, Kikatani Y, Yokota K, Tsukagoshi S, Sakurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 44:4303-4307, 1984.
67. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981.
68. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski FP, Chassagne J: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111-116, 1991.
69. Xie XY, Robb D, Chow S, Hedley DW: Disconcordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 9:1882-1887, 1995.
70. Yanovich S, Taub R: Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res 43:4167-4172, 1983.
71. Zaman GJR, Flens MJ, van Leusden MR, de Hass M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci 91:8822-8826, 1994.
72. Zijlstra JG, de Vries EGE, Mulder NH: Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47:1780-1784, 1984.